Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Vivid Dx raises $15M in seed financing to enhance pathogen detection and combat drug-resistant infections, led by Oxford Science Enterprises and Cedars-Sinai.
Vivid Dx has secured $15 million in seed financing to advance its precision diagnostics for drug-resistant infections. This funding, co-led by Oxford Science Enterprises and Cedars-Sinai Intellectual Property Co., aims to improve pathogen detection. The investment will support the company's efforts to enhance diagnostics that are critical in hospital settings. Additionally, Vivid Dx has appointed Keith O'Neill as CEO to lead its next phase of development.
Company Information
Company
Vivid Dx
Location
Oxford, England, United Kingdom
About
Vivid Dx is a precision diagnostics company transforming pathogen detection and antimicrobial resistance testing. The company is developing a next-generation platform to deliver broad pathogen ID in 30 minutes and antibiotic susceptibility testing in 3 hours directly from blood. A spin-out from the University of Oxford, Vivid Dx aims to redefine the speed and accuracy of infectious disease diagnostics.
OxfordBiotechnologyHealth CareHealth Diagnostics